Zacks Research Has Bearish Estimate for TEVA Q3 Earnings

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) - Stock analysts at Zacks Research cut their Q3 2025 earnings per share estimates for Teva Pharmaceutical Industries in a report released on Wednesday, May 28th. Zacks Research analyst R. Department now forecasts that the company will earn $0.69 per share for the quarter, down from their previous estimate of $0.71. The consensus estimate for Teva Pharmaceutical Industries' current full-year earnings is $2.50 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries' Q4 2025 earnings at $0.60 EPS, FY2025 earnings at $2.40 EPS, Q1 2026 earnings at $0.48 EPS, Q2 2026 earnings at $0.64 EPS, Q3 2026 earnings at $0.79 EPS, FY2026 earnings at $2.60 EPS, Q1 2027 earnings at $0.64 EPS and FY2027 earnings at $2.80 EPS.

Other research analysts have also recently issued research reports about the stock. Bank of America upped their target price on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Hsbc Global Res raised Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. Truist Financial assumed coverage on Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price objective for the company. Finally, JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and increased their price target for the stock from $21.00 to $23.00 in a research note on Monday, May 12th. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $24.50.

Teva Pharmaceutical Industries Stock Performance

Shares of Teva Pharmaceutical Industries stock traded down $0.29 during trading on Monday, hitting $17.24. 10,909,379 shares of the stock were exchanged, compared to its average volume of 10,135,027. The stock's fifty day moving average is $15.67 and its 200 day moving average is $17.38. The stock has a market cap of $19.54 billion, a PE ratio of -11.89, a P/E/G ratio of 1.44 and a beta of 0.62. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. Teva Pharmaceutical Industries has a 12 month low of $12.47 and a 12 month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. The firm had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. The firm's revenue was up 1.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.48 EPS.

Insider Activity

In related news, EVP Matthew Shields sold 6,206 shares of the firm's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total transaction of $105,626.12. Following the completion of the transaction, the executive vice president now owns 9,989 shares of the company's stock, valued at $170,012.78. This trade represents a 38.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.49% of the company's stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Large investors have recently made changes to their positions in the business. Robeco Institutional Asset Management B.V. grew its position in Teva Pharmaceutical Industries by 7.2% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company's stock worth $10,983,000 after buying an additional 33,277 shares during the last quarter. Pinnbrook Capital Management LP bought a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth $4,966,000. Asset Management One Co. Ltd. boosted its stake in shares of Teva Pharmaceutical Industries by 14.6% during the 4th quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company's stock worth $10,414,000 after acquiring an additional 58,413 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of Teva Pharmaceutical Industries by 2,018.3% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,097,096 shares of the company's stock worth $23,368,000 after acquiring an additional 1,045,305 shares in the last quarter. Finally, Capital Wealth Planning LLC boosted its stake in shares of Teva Pharmaceutical Industries by 8.8% during the 4th quarter. Capital Wealth Planning LLC now owns 246,601 shares of the company's stock worth $5,435,000 after acquiring an additional 20,016 shares in the last quarter. Institutional investors own 54.05% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.